Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide plus IMRT versus IMRT alone for high-risk low-grade glioma
ChiCTR1800017799Phase 3Recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Sep 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of temozolomide in glioma (2 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Progression-free survival. Started Sep 2018; status: recruiting.
02
Drugs
temozolomide
03
Conditions
glioma
Beyond the preview
Go deeper on ChiCTR1800017799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017799.